Postmenopausal women who live in U.S. counties with the highest radon levels are significantly more likely to develop ovarian cancer than those in lower-radon areas, according to a study published in April 2026 in JAMA Network Open. Researchers at the University of North Dakota School of Medicine analyzed data from more than 160,000 women enrolled in the Women’s Health Initiative, a landmark federal study that has tracked postmenopausal health outcomes for decades. Their finding marks the first time a large prospective cohort study has tied residential radon exposure to ovarian cancer, a disease the American Cancer Society estimates kills roughly 13,000 American women each year.
Radon is a colorless, odorless radioactive gas that seeps into buildings from uranium decaying naturally in soil. Federal agencies have long recognized it as the second leading cause of lung cancer in the United States, behind smoking. But until now, no major study had examined whether the gas might threaten organs beyond the lungs.
What the researchers found
The UND team, led by epidemiologists at the university’s medical school, matched each participant’s county of residence to the EPA’s Map of Radon Zones. That classification system sorts every U.S. county into three tiers based on predicted average indoor radon concentrations. Zone 1, the highest tier, includes counties where indoor levels are expected to exceed 4 picocuries per liter (pCi/L), the threshold at which the EPA recommends mitigation. Many Zone 1 counties cluster across the upper Midwest, northern Great Plains, and parts of Appalachia.
Women living in Zone 1 counties showed a statistically significant increase in ovarian cancer incidence compared with women in Zone 3 (lowest radon) counties. The WHI’s cancer outcomes are not simply pulled from billing codes; each case undergoes physician review and standardized classification, as documented in the initiative’s outcomes adjudication manual. That clinical rigor reduces the chance that ovarian cancers were miscounted or confused with other diagnoses.
The radon exposure estimates themselves rest on decades of federal geophysical mapping. The U.S. Geological Survey’s Open-File Report 93-292, produced under an interagency agreement with the EPA, remains the foundational assessment of geologic radon potential nationwide. It integrates soil-gas measurements, indoor radon readings, and gamma radiation surveys, including data from a separate USGS technical report on terrestrial radioactivity, to estimate how likely buildings in a given area are to have elevated radon.
What remains uncertain
The study establishes a statistical association, not a proven cause-and-effect relationship. Radon’s known cancer pathway involves alpha particles tearing through lung tissue and triggering DNA mutations. How those particles might damage ovarian cells is far less understood. One hypothesis the research team raised is that radon exposure could interact with hormonal changes in postmenopausal women, amplifying cancer risk beyond direct radiation damage. No laboratory or clinical evidence has confirmed that mechanism.
County-level radon classification is also an imperfect stand-in for personal exposure. The EPA’s zone designations reflect geologic predictions, not actual measurements inside each participant’s home. The CDC’s Environmental Public Health Tracking Network publishes county-level radon testing data, but coverage is uneven: many counties report few or zero buildings tested. A woman assigned to a high-radon county may have lived in a well-ventilated home with low indoor levels, while someone in a low-radon county could have unknowingly occupied a localized hotspot.
Other confounders are difficult to fully separate. Housing stock, smoking history, occupational exposures, socioeconomic status, and access to gynecologic care can all vary between high- and low-radon regions. The UND analysis adjusted for several of these factors, but the authors acknowledge that residual confounding cannot be ruled out in any observational study of this design.
No official EPA or USGS statement has addressed the ovarian cancer connection as of late April 2026. Federal radon guidance still focuses exclusively on lung cancer, and the study’s authors have framed their work as hypothesis-generating rather than a basis for new screening protocols or revised exposure limits.
Why the evidence matters now
Ovarian cancer is notoriously hard to catch early. There is no reliable screening test for the general population, and most cases are diagnosed at an advanced stage, when five-year survival rates drop sharply. If radon turns out to be a genuine contributing factor, it would represent one of the few modifiable environmental risks ever identified for the disease. That alone makes the UND finding worth serious follow-up, even before the mechanism is nailed down.
Confirmatory research would need to go further than county-level estimates. Studies using direct indoor radon measurements, personal dosimeters, or biomarkers of radiation exposure could move the evidence from correlation toward causation. Laboratory work on how alpha radiation interacts with ovarian tissue or hormonal pathways would help clarify whether the biological story holds up.
What women and policymakers can do right now
For women in Zone 1 counties, the most practical response is also the cheapest. Short-term radon test kits cost under $20 and are available at most hardware stores or through state radon programs. If results come back at or above 4 pCi/L, the EPA recommends professional mitigation, typically a sub-slab depressurization system that vents gas from beneath the foundation to the outside. The new study does not prove that mitigation will reduce ovarian cancer risk, but it is already an evidence-based intervention for lung cancer prevention and carries no downside.
For public health officials, the findings expose a structural gap. Radon programs tend to sit inside environmental or housing agencies, while ovarian cancer initiatives live within cancer control or women’s health offices. Bridging those silos would not require waiting years for definitive mechanistic studies. Integrating radon testing information into gynecologic health outreach in high-radon regions, for example, is a low-cost step that could raise awareness where it matters most.
The core message that has guided radon policy for decades has not changed: every household should know its indoor radon level, and the safest exposure is as low as reasonably achievable. What this research adds is a new dimension to the risk profile. For postmenopausal women living in the counties mapped as having the highest geologic radon potential, the gas may pose a broader threat than lung cancer alone. Testing and mitigation remain the immediate, actionable steps, but the stakes for women’s health may be larger than anyone previously recognized.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
